Skip to content
Study details
Enrolling now

At-BC8-B10 Trial Before Stem Cell Transplant

Fred Hutchinson Cancer Center
NCT IDNCT03128034ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

75

Study length

about 11 years

Ages

18–75

Locations

1 site in WA

What this study is about

This trial is testing a treatment called At-BC8-B10 before donor stem cell transplant in people with high-risk leukemia. The goal is to find the best dose of this treatment and see how it affects patients.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Pretargeted Radioimmunotherapy
  • 2.Receive Total-Body Irradiation
  • 3.Take Cyclosporine
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

ciclosporin, Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), Immunological Agents (Enzyme Inhibitors)

Drug routes

injection, intravenous, injection (Injection)

Endpoints

Primary: Incidence of grades III/IV Bearman regimen-related toxicity

Secondary: Disease-free survival, Non-relapse mortality, Overall survival

Procedures

diagnostic, imaging, radiation

Body systems

Oncology